以雷贝拉唑为基础的不同疗程三联疗法治疗幽门螺杆菌感染疗效的Meta分析  

Meta analysis:the efficacy of rabeprazole-based triple therapy for H.pylori infection with different courses

作　　者：童婷婷[1] 姜政[1] 刘畅[1] 曹国栋[1] 胡丹[1] 

机构地区：[1]重庆医科大学附属第一医院消化内科,400016

出　　处：《重庆医学》2016年第15期2095-2099,共5页Chongqing medicine

摘　　要：目的对以雷贝拉唑为基础的三联疗法根治幽门螺杆菌（H.pylori）感染7、10、14d疗效进行Meta分析,以客观评价其疗效。方法计算机检索维普数据库、万方数据库、中国知网数据库（CNKI）、PubMed数据库,查找以雷贝拉唑为基础的不同疗程三联疗法治疗H.pylori感染的相关文献,运用Review Manager5.2软件对文献数据进行分析。结果以雷贝拉唑为基础的三联疗法在H.pylori根除率方面,10d和14d疗程效果优于7d疗程,差异具有统计学意义（7dvs.10dOR=0.72,95%CI：0.53-0.96,P=0.030;7dvs.14dOR=0.49,95%CI：0.31-0.79,P=0.003）,但10d和14d疗程差异无统计学意义（OR=0.79,95%CI：0.47-1.34,P=0.390）;在不良反应发生率方面,7、10、14d3个疗程分别两两组间对比,差异均无统计学意义（7d vs.10dOR=1.05,95%CI：0.75-1.47,P=0.780;7dvs.14dOR=0.80,95%CI：0.32-2.00,P=0.630;10dvs.14dOR=0.82,95%CI：0.45-1.50,P=0.530）;在临床症状缓解率方面,上述各组间对比亦无统计学证据支持何种疗程更加有效（7dvs.10d;OR=0.79,95%CI：0.31-2.04,P=0.630;7dvs.14d：OR=0.72,95%CI：0.26-2.00,P=0.530;10dvs.14d：OR=0.92,95%CI：0.32-2.63,P=0.870）。结论在以雷贝拉唑为基础的三联疗法治疗H.pylori感染时,结合患者经济负担及依从性考虑,建议用药10d则可达到治疗目的。Objective To objectively evaluate the efficacy of rabeprazole-based triple therapy for the treatment of H.pylori infection with different courses including 7days,10 days,and 14 days.Methods Databases of VIP database,Wanfang database,CNKI,PubMed were searched for the related literature on rabeprazole-based triple therapy treating H.pylori infection in different courses.The useful data was analyzed by statistical software Review Manager 5.2.Results With rabepaazole-based triple therapy,the H.pylori eradication rates were higher in 10-day-course and 14-day-course than in 7-day-course（7dvs.10dOR=0.72,95%CI：0.53-0.96,P=0.030;7dvs.14dOR=0.49,95%CI：0.31-0.79,P=0.003）.However,there was no statistical significance between 10-day-course and 14-day-course（OR=0.79,95%CI：0.47-1.34,P=0.390）.In addition,we had compared the incidence of adverse reactions between the groups of 7-day-course,10-day-course,and 14-day-course,and it revealed that there were no significant differences between them（7dvs.10dOR=1.05,95%CI：0.75-1.47,P=0.780;7dvs.14dOR=0.80,95%CI：0.32-2.00,P=0.630;10dvs.14dOR=0.82,95%CI：0.45-1.50,P=0.530）.Similarly,as for the clinical manifestation remission rates,we also found there were no statistical evidences to indicate which kind of treatment was more effective among the three courses stated above（7dvs.10dOR=0.79,95%CI：0.31-2.04,P=0.630;7dvs.14d：OR=0.72,95%CI：0.26-2.00,P=0.530;10dvs.14d：OR=0.92,95%CI：0.32-2.63,P=0.870）.Conclusion When rabeprazole-based triple therapy was selected for the treatment of H.pylori infection,the 10-day-course treatment might be a better choice considering about the economic burden and medication adherence of patients.

关 键 词：螺杆菌 幽门 螺杆菌感染 雷贝拉唑 三联疗法 疗程 META分析 

分 类 号：R573[医药卫生—消化系统]